BioHarvest Sciences Inc. (BHST)
- Previous Close
6.12 - Open
6.17 - Bid 6.56 x 100
- Ask 6.75 x 100
- Day's Range
6.12 - 6.38 - 52 Week Range
0.00 - 7.38 - Volume
10,027 - Avg. Volume
23,344 - Market Cap (intraday)
109.043M - Beta (5Y Monthly) 1.33
- PE Ratio (TTM)
-- - EPS (TTM)
-0.45 - Earnings Date May 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.75
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through Nutraceuticals and Pharmaceuticals segments. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional foods, as well as manufacturing, marketing, and sale of science-based health and cosmeceutical solutions. The company also provides contract development and manufacturing operation services. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red wine. The company is based in Vancouver, Canada.
www.bioharvest.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BHST
View MorePerformance Overview: BHST
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BHST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BHST
View MoreValuation Measures
Market Cap
109.04M
Enterprise Value
122.73M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.88
Price/Book (mrq)
--
Enterprise Value/Revenue
4.43
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-51.27%
Return on Assets (ttm)
-21.84%
Return on Equity (ttm)
--
Revenue (ttm)
25.19M
Net Income Avi to Common (ttm)
-12.91M
Diluted EPS (ttm)
-0.45
Balance Sheet and Cash Flow
Total Cash (mrq)
2.39M
Total Debt/Equity (mrq)
1,038.95%
Levered Free Cash Flow (ttm)
-3.86M